Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SXL01 in Metastatic Castration-Resistant Prostate Cancer
NCT02866916Phase 1Withdrawn
- Sponsor
- Institut Claudius Regaud
- Start
- Sep 2017
- Primary completion
- Jun 2020
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SXL01 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Institut Claudius Regaud. Primary endpoints: Incidence rate of Dose Limiting Toxicities at 25 months, Characteristics of Dose Limiting Toxicities at 25 months and 1 more. Planned start Sep 2017; status: withdrawn.
02
Drugs
SXL01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02866916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02866916.